Akari Therapeutics Plc - ADR
AKTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.69M
Close$
$5.29
39.7% downside
Current Fair Value
39.7% downsideOvervalued by 39.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $15.69 Million |
|---|---|
| Enterprise Value | $8.69 Million |
| Earnings per Share | $-20800 |
| Beta | 1.44 |
| Outstanding Shares | 1,791,468 |
Return
| Return on Equity | -166.70% |
|---|---|
| Return on Assets | -80.26% |
| Return on Invested Capital | -128.09% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.27 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-1.04
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
December 4, 2026
EPS Estimate
$-2.23
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 8.37% |
|---|---|
| Total Invested | $93▼ 99.99% |
| Investors Holding | 1▼ 9.00% |
About Akari Therapeutics Plc
CEO: David Solomon
